硫胺化合物的CA IX抑制:对抗乳腺癌的治疗方法
Sükrü Akmese1, Ebru Temiz2, Elif Gürel3
1Department of Medicinal Biochemistry, Medical Faculty, Harran University, Sanlıurfa, Turkey.
Chemistry & biodiversity
|March 13, 2026
概括
这项研究表明,硫胺衍生物MMH-I在乳腺癌模型中有效向碳酸无水酶IX (CA IX). MMH-I 降低了瘤生长,促进了癌细胞死亡,表明其作为新型治疗剂的潜力.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 碳酸无水酶IX (CA IX) 是一种在固体瘤中过度表达的关键酶,驱动癌症的进展.
- 硫胺衍生物正在作为癌症治疗的潜在CA IX抑制剂进行研究.
研究的目的:
- 评估硫胺衍生物MMH-I的抗癌潜力和治疗疗效.
- 评估MMH-I在体外和体内乳腺癌模型中的CA IX向活性.
主要方法:
- 细胞毒性通过MTT测定进行评估;通过色酸/乙化染色和Annexin V检测评估的细胞亡.
- 在体内研究包括瘤体积测量,CA IX,维门丁,E-Cadherin,Caspase-3分析,H&E染色和血代谢学.
主要成果:
- MMH-I显著降低了瘤体积,并在乳腺癌细胞中诱导了亡.
- 该化合物改变了与癌症相关的基因和代谢资料的表达,CA IX,维丁,E-Cadherin和Caspase-3水平的显著变化.
结论:
- 在临床前乳腺癌模型中,MMH-I显示出显著的抗癌活性和CA IX向潜力.
- MMH-I值得进一步研究作为治疗候选者,可能用于低氧瘤的组合策略.
相关概念视频
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
02:34Inhibition of CDK Activity
5.6K
5.6K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K